Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]


  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

Sign up for updates
    • 11/06/2021
    • Articles

    Belgium - Constitutional Court Rejects Challenge to Statutory Medicine Shortage Rules, Including Export Restrictions

    The Constitutional Court dismissed on 10 June 2021 the action which the Belgian Association of Parallel Importers and Exporters, several other parties active in the parallel trade in medicines, and pharmacists in the Democratic Republic of the Congo and Rwanda (the Applicants) had brought to obtain the annulment of Articles 2, 3 and 4 of the Law of 20 December 2019 modifying various laws to tackle medicine shortages (Wet van 20 december 2019 tot wijziging van diverse wetgevingen wat de tekorten aan geneesmiddelen betreft/Loi du 20 décembre 2020 modifiant diverses législations, en ce qui concerne les pénuries de médicaments – the Law). The Constitutional Court had already rejected a request for suspension of the same provisions (see, Van Bael & Bellis News and Insights of 20 July 2020). Yesterday’s judgment (see, attachments) focused on the powers given by statute to the government to establish a procedure for the creation of a temporary limitation or prohibition of the exportation of medicines that are unavailable on the Belgian market. The Applicants relied on the European free movement of goods principles but also on several provisions of Belgian law to challenge these restrictions. However, the Constitutional Court considered the contested rules justified in that they permit the government to counter situations in which medicine supplies to Belgian patients are no longer guaranteed. The Constitutional Court distinguished the new rules, which will be applied on a case-by-case basis following an assessment of the causes and nature of the particular shortage afflicting a specific medicine, from the blanket export prohibition imposed on wholesaler-distributors which it struck down in 2019 (see, Van Bael & Bellis Life Sciences News and Insights of 19 July 2019 and 17 October 2019). As the Constitutional Court has allowed the challenged statutory medicine shortage rules to stand, the question arises when the government will come up with the requisite implementing rules. Pressed on the subject in Parliament, the Minister of Social Affairs and Public Health indicated back in February 2021 that these proposed rules are under review, but he did not give a timetable for their adoption. Four months later, it is still not clear when they will become law.

    Read more
    • 01/06/2021
    • Articles

    Belgian DPA Approves First European Code of Conduct

    On 20 May 2021, the Belgian Data Protection Authority (Gegevensbeschermingsautoriteit / Autorité de protection des données – the DPA) approved the first transnational code of conduct to be adopted within the European Union since the entry into force of General Data Protection Regulation (EU) 2016/679 (the GDPR). The “EU Data Protection Code of Conduct for Cloud Service Providers” (the EU Cloud CoC) aims to establish good data protection practices for cloud service providers and wishes to contribute to a better protection of personal data processed in the cloud in Europe. One day earlier, on 19 May 2021, the European Data Protection Board issued a favourable opinion, allowing the DPA to approve the first transnational code of conduct. In its approval decision, the DPA underlines the importance of codes of conduct as voluntary accountability tools to tailor data protection rules to the specificities of a sector. By adhering to the code, companies will ensure that data handling is in line with the GDPR. Adherence to the EU Cloud CoC is also achievable for small and medium enterprises that are active in this sector. Please click below to read our note on the Code of Conduct.

    Read more
    • 31/05/2021
    • Articles

    Medical Devices - Free Market Access between European Union and Switzerland Given Blow

    Regulation (EU) 2017/745, the new Medical Device Regulation (MDR), started to apply on 26 May 2021, more than four years after its adoption in April 2017. However, this important step in the development of the regulatory framework governing medical devices coincided with a shrinking of the internal market for these products as trade in medical devices between the European Union (EU) and Switzerland became subject to more red tape. This is because the chapter covering medical devices of the EU – Switzerland Mutual Recognition Agreement (MRA) has not been updated to reflect the application of the MDR (see, the attached European Commission Notice to Stakeholders – the Notice). The failure to modernise the MRA is ironic, because both sides have tightened their requirements with respect to medical devices, mainly to improve safety and increase regulatory oversight. Even though the regulatory adjustments to EU and Swiss medical device rules are thus largely comparable, reciprocal free market access has fallen by the wayside because of the EU’s insistence that no piecemeal regulatory adaptations in areas of mutual interest will be made as long as the parties do not agree on an overarching Institutional Framework Agreement (IFA). Negotiations in pursuit of the IFA started in 2014, but were terminated by Switzerland on 26 May 2021, which thus added further complications to an eventful day. The EU and Switzerland apparently anticipated these developments and, based on a proposal submitted by the European Commission, have tried to work out transitional arrangements for the MRA, including a grace period until 2024, but these talks failed as well. The consequences for the EU-Swiss trade in medical devices are devastating as Switzerland exports more than EUR 4.5bn worth of medical devices to the EU, while it imports over EUR 2.4bn. Even though this trade will not dry up, it will become harder to sustain. Similarly, investment decisions, primarily those directed at Switzerland, may also be affected. Industry will have to contend with additional expenses because the trade facilitating measures of the MRA no longer apply. Market surveillance will also be adversely affected. And new regulatory burdens will emerge. For its part, Switzerland has put in place measures to mitigate these negative effects. For example, the measures will ensure the equivalence of the Swiss rules governing medical devices to those of the EU. Additionally, importers in Switzerland will be given time to appoint an authorised representative, adjust labelling, carry out registrations with Swissmedic, the Swiss regulatory authority, and effect specific publications. Conversely, there are no transitional rules that apply to importers in the EU. As a result and as explained in the Notice, since 26 May 2021, these businesses are required to: • ensure that medical devices are certified by an EU conformity assessment body if such a certification is dictated by the applicable conformity assessment procedure; • designate an EU authorised representative; • observe the rules governing the registration and labelling of products.

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.